Cardiff OncologyCRDF
Market Cap: $98.2M
About: Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Employees: 32
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
683% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $238K
167% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 12
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
17% more funds holding
Funds holding: 76 [Q1] → 89 (+13) [Q2]
9.71% more ownership
Funds ownership: 18.9% [Q1] → 28.6% (+9.71%) [Q2]
37% less capital invested
Capital invested by funds: $45M [Q1] → $28.4M (-$16.6M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Craig-Hallum Albert Lowe 33% 1-year accuracy 1 / 3 met price target | 279%upside $8 | Buy Initiated | 6 Sept 2024 |